Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice

Salvatore Cuzzocrea, Rosanna Di Paola, Emanuela Mazzon, N. S A Patel, Tiziana Genovese, Carmelo Muià, Concetta Crisafulli, Achille P. Caputi, Christoph Thiemermann

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: Erythropoietin is a potent stimulator of erythroid progenitor cells, and its expression is enhanced by hypoxia. In the present study, we investigated the effects of erythropoietin (1000 IU/kg subcutaneously) on the development of nonseptic shock caused by zymosan. Design: Prospective, randomized study. Setting: University-based research laboratory. Subjects: Male CD mice. Interventions: Mice received either intraperitoneally zymosan (500 mg/kg, administered intraperitoneally as a suspension in saline) or vehicle (0.25 mL/mouse saline). Erythropoietin was administered at the dose of 1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration. Organ failure and systemic inflammation in mice was assessed 18 hrs after administration of zymosan and/or erythropoietin. Measurements and Main Results: Treatment of mice with erythropoietin (1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. Erythropoietin also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity caused by zymosan in the lung and intestine. Immunohistochemical analysis for nitrotyrosine and poly(ADP-ribose) revealed positive staining in lung and intestine tissues obtained from zymosan-treated mice. The degree of staining for nitrotyrosine and poly(ADP-ribose) was markedly reduced in tissue sections obtained from zymosan-treated mice, which received erythropoietin. In addition, administration of zymosan caused severe illness in the mice characterized by a systemic toxicity, significant loss of body weight, and a 70% mortality rate at the end of observation period (7 days). Treatment with erythropoietin significantly reduced the development of systemic toxicity, the loss in body weight, and the mortality caused by zymosan. Conclusions: This study provides evidence, for the first time, that erythropoietin attenuates the degree of zymosan-induced nonseptic shock in mice.

Original languageEnglish
Pages (from-to)1168-1177
Number of pages10
JournalCritical Care Medicine
Volume34
Issue number4
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Zymosan
Erythropoietin
Shock
Poly Adenosine Diphosphate Ribose
Lung
Intestines
Body Weight
Staining and Labeling
Erythroid Precursor Cells
Mortality
Peroxidase
Cell Movement
Suspensions

Keywords

  • Cytokines
  • Inducible nitric oxide synthase
  • Inflammation
  • Nitric oxide
  • Proliferator-activated receptor-γ
  • Zymosan-induced multiple organ failure

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Cuzzocrea, S., Di Paola, R., Mazzon, E., Patel, N. S. A., Genovese, T., Muià, C., ... Thiemermann, C. (2006). Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Critical Care Medicine, 34(4), 1168-1177. https://doi.org/10.1097/01.CCM.0000207346.56477.E8

Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. / Cuzzocrea, Salvatore; Di Paola, Rosanna; Mazzon, Emanuela; Patel, N. S A; Genovese, Tiziana; Muià, Carmelo; Crisafulli, Concetta; Caputi, Achille P.; Thiemermann, Christoph.

In: Critical Care Medicine, Vol. 34, No. 4, 04.2006, p. 1168-1177.

Research output: Contribution to journalArticle

Cuzzocrea, S, Di Paola, R, Mazzon, E, Patel, NSA, Genovese, T, Muià, C, Crisafulli, C, Caputi, AP & Thiemermann, C 2006, 'Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice', Critical Care Medicine, vol. 34, no. 4, pp. 1168-1177. https://doi.org/10.1097/01.CCM.0000207346.56477.E8
Cuzzocrea, Salvatore ; Di Paola, Rosanna ; Mazzon, Emanuela ; Patel, N. S A ; Genovese, Tiziana ; Muià, Carmelo ; Crisafulli, Concetta ; Caputi, Achille P. ; Thiemermann, Christoph. / Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. In: Critical Care Medicine. 2006 ; Vol. 34, No. 4. pp. 1168-1177.
@article{ca70071f466d4920b68c01135b84659d,
title = "Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice",
abstract = "Objective: Erythropoietin is a potent stimulator of erythroid progenitor cells, and its expression is enhanced by hypoxia. In the present study, we investigated the effects of erythropoietin (1000 IU/kg subcutaneously) on the development of nonseptic shock caused by zymosan. Design: Prospective, randomized study. Setting: University-based research laboratory. Subjects: Male CD mice. Interventions: Mice received either intraperitoneally zymosan (500 mg/kg, administered intraperitoneally as a suspension in saline) or vehicle (0.25 mL/mouse saline). Erythropoietin was administered at the dose of 1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration. Organ failure and systemic inflammation in mice was assessed 18 hrs after administration of zymosan and/or erythropoietin. Measurements and Main Results: Treatment of mice with erythropoietin (1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. Erythropoietin also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity caused by zymosan in the lung and intestine. Immunohistochemical analysis for nitrotyrosine and poly(ADP-ribose) revealed positive staining in lung and intestine tissues obtained from zymosan-treated mice. The degree of staining for nitrotyrosine and poly(ADP-ribose) was markedly reduced in tissue sections obtained from zymosan-treated mice, which received erythropoietin. In addition, administration of zymosan caused severe illness in the mice characterized by a systemic toxicity, significant loss of body weight, and a 70{\%} mortality rate at the end of observation period (7 days). Treatment with erythropoietin significantly reduced the development of systemic toxicity, the loss in body weight, and the mortality caused by zymosan. Conclusions: This study provides evidence, for the first time, that erythropoietin attenuates the degree of zymosan-induced nonseptic shock in mice.",
keywords = "Cytokines, Inducible nitric oxide synthase, Inflammation, Nitric oxide, Proliferator-activated receptor-γ, Zymosan-induced multiple organ failure",
author = "Salvatore Cuzzocrea and {Di Paola}, Rosanna and Emanuela Mazzon and Patel, {N. S A} and Tiziana Genovese and Carmelo Mui{\`a} and Concetta Crisafulli and Caputi, {Achille P.} and Christoph Thiemermann",
year = "2006",
month = "4",
doi = "10.1097/01.CCM.0000207346.56477.E8",
language = "English",
volume = "34",
pages = "1168--1177",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice

AU - Cuzzocrea, Salvatore

AU - Di Paola, Rosanna

AU - Mazzon, Emanuela

AU - Patel, N. S A

AU - Genovese, Tiziana

AU - Muià, Carmelo

AU - Crisafulli, Concetta

AU - Caputi, Achille P.

AU - Thiemermann, Christoph

PY - 2006/4

Y1 - 2006/4

N2 - Objective: Erythropoietin is a potent stimulator of erythroid progenitor cells, and its expression is enhanced by hypoxia. In the present study, we investigated the effects of erythropoietin (1000 IU/kg subcutaneously) on the development of nonseptic shock caused by zymosan. Design: Prospective, randomized study. Setting: University-based research laboratory. Subjects: Male CD mice. Interventions: Mice received either intraperitoneally zymosan (500 mg/kg, administered intraperitoneally as a suspension in saline) or vehicle (0.25 mL/mouse saline). Erythropoietin was administered at the dose of 1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration. Organ failure and systemic inflammation in mice was assessed 18 hrs after administration of zymosan and/or erythropoietin. Measurements and Main Results: Treatment of mice with erythropoietin (1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. Erythropoietin also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity caused by zymosan in the lung and intestine. Immunohistochemical analysis for nitrotyrosine and poly(ADP-ribose) revealed positive staining in lung and intestine tissues obtained from zymosan-treated mice. The degree of staining for nitrotyrosine and poly(ADP-ribose) was markedly reduced in tissue sections obtained from zymosan-treated mice, which received erythropoietin. In addition, administration of zymosan caused severe illness in the mice characterized by a systemic toxicity, significant loss of body weight, and a 70% mortality rate at the end of observation period (7 days). Treatment with erythropoietin significantly reduced the development of systemic toxicity, the loss in body weight, and the mortality caused by zymosan. Conclusions: This study provides evidence, for the first time, that erythropoietin attenuates the degree of zymosan-induced nonseptic shock in mice.

AB - Objective: Erythropoietin is a potent stimulator of erythroid progenitor cells, and its expression is enhanced by hypoxia. In the present study, we investigated the effects of erythropoietin (1000 IU/kg subcutaneously) on the development of nonseptic shock caused by zymosan. Design: Prospective, randomized study. Setting: University-based research laboratory. Subjects: Male CD mice. Interventions: Mice received either intraperitoneally zymosan (500 mg/kg, administered intraperitoneally as a suspension in saline) or vehicle (0.25 mL/mouse saline). Erythropoietin was administered at the dose of 1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration. Organ failure and systemic inflammation in mice was assessed 18 hrs after administration of zymosan and/or erythropoietin. Measurements and Main Results: Treatment of mice with erythropoietin (1000 IU/kg subcutaneously, 1 and 6 hrs after zymosan administration) attenuated the peritoneal exudation and the migration of polymorphonuclear cells caused by zymosan. Erythropoietin also attenuated the lung, liver, and pancreatic injury and renal dysfunction caused by zymosan as well as the increase in myeloperoxidase activity caused by zymosan in the lung and intestine. Immunohistochemical analysis for nitrotyrosine and poly(ADP-ribose) revealed positive staining in lung and intestine tissues obtained from zymosan-treated mice. The degree of staining for nitrotyrosine and poly(ADP-ribose) was markedly reduced in tissue sections obtained from zymosan-treated mice, which received erythropoietin. In addition, administration of zymosan caused severe illness in the mice characterized by a systemic toxicity, significant loss of body weight, and a 70% mortality rate at the end of observation period (7 days). Treatment with erythropoietin significantly reduced the development of systemic toxicity, the loss in body weight, and the mortality caused by zymosan. Conclusions: This study provides evidence, for the first time, that erythropoietin attenuates the degree of zymosan-induced nonseptic shock in mice.

KW - Cytokines

KW - Inducible nitric oxide synthase

KW - Inflammation

KW - Nitric oxide

KW - Proliferator-activated receptor-γ

KW - Zymosan-induced multiple organ failure

UR - http://www.scopus.com/inward/record.url?scp=33645831368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645831368&partnerID=8YFLogxK

U2 - 10.1097/01.CCM.0000207346.56477.E8

DO - 10.1097/01.CCM.0000207346.56477.E8

M3 - Article

VL - 34

SP - 1168

EP - 1177

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 4

ER -